Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Holmvang

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|February 24, 2001
[Eptifibatide (Integrilin)]L Holmvang, P Grande
American Heart Journal|January 8, 1999
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial InfarctionL Holmvang, P Clemmensen, G Wagner, et al.
Ugeskrift for Laeger|October 26, 1992
[Thrombocyte aggregation and serum thromboxane B2 in patients with unstable angina pectoris treated with diltiazem or verapamil]F Lyck, L Holmvang, A M Grauholt, et al.
Journal of Electrocardiology|February 25, 2000
"Add-on" research in clinical trials: are we asking the right questions?P Clemmensen, L Holmvang, P Grande, et al.
The American Journal of Cardiology|July 22, 1998
Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy)L Holmvang, P Hasbak, P Clemmensen, et al.
Journal of Electrocardiology|February 13, 1999
Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy)L Holmvang, P Hasbak, P Clemmensen, et al.
The American Journal of Cardiology|June 26, 2001
Excellent prognosis in patients with unstable angina pectoris classified as "low risk" at admission despite presence of severe coronary artery diseaseL Holmvang, B Jurlander, P Leibrandt, et al.
European Heart Journal|April 20, 1999
Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery DiseaseH Sätre, L Holmvang, G S Wagner, et al.
Circulation|November 10, 1998
Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study GroupL Holmvang, M S Lüscher, P Clemmensen, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 8, 2017
Drop-out from cardiovascular magnetic resonance in a randomized controlled trial of ST-elevation myocardial infarction does not cause selection bias on endpointsPeter Nørkjær Laursen, L Holmvang, H Kelbæk, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|February 24, 2001
[Eptifibatide (Integrilin)]L Holmvang, P Grande
American Heart Journal|January 8, 1999
Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial InfarctionL Holmvang, P Clemmensen, G Wagner, et al.
Ugeskrift for Laeger|October 26, 1992
[Thrombocyte aggregation and serum thromboxane B2 in patients with unstable angina pectoris treated with diltiazem or verapamil]F Lyck, L Holmvang, A M Grauholt, et al.
Journal of Electrocardiology|February 25, 2000
"Add-on" research in clinical trials: are we asking the right questions?P Clemmensen, L Holmvang, P Grande, et al.
The American Journal of Cardiology|July 22, 1998
Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy)L Holmvang, P Hasbak, P Clemmensen, et al.
Journal of Electrocardiology|February 13, 1999
Differences between local investigator and core-laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy)L Holmvang, P Hasbak, P Clemmensen, et al.
The American Journal of Cardiology|June 26, 2001
Excellent prognosis in patients with unstable angina pectoris classified as "low risk" at admission despite presence of severe coronary artery diseaseL Holmvang, B Jurlander, P Leibrandt, et al.
European Heart Journal|April 20, 1999
Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery DiseaseH Sätre, L Holmvang, G S Wagner, et al.
Circulation|November 10, 1998
Very early risk stratification using combined ECG and biochemical assessment in patients with unstable coronary artery disease (A thrombin inhibition in myocardial ischemia [TRIM] substudy). The TRIM Study GroupL Holmvang, M S Lüscher, P Clemmensen, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 8, 2017
Drop-out from cardiovascular magnetic resonance in a randomized controlled trial of ST-elevation myocardial infarction does not cause selection bias on endpointsPeter Nørkjær Laursen, L Holmvang, H Kelbæk, et al.
Pageof 2